ArticleParasites & vectors2024
Evaluating the significance of Toxoplasma gondii sporozoite antibodies in cats: a pilot study.
Article in Parasites & vectors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seroprevalence of Toxoplasma gondii and associated demographic factors in privately-owned dogs, cats, and community cats in Hong Kong.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople can acquire Toxoplasma gondii infection by ingestion of sporulated oocysts passed in cat feces; whether this route is common in cats is unknown. The primary objectives of this study were to (a) adapt a commercially available enzyme-linked immunosorbent assay (ELISA) for the detection of T. gondii tachyzoite IgG antibodies in feline sera to detect T. gondii sporozoite IgG antibodies, (b) utilize the ELISA to confirm that exposed cats can mount an antibody response to sporozoites, (c) estimate the prevalence of sporozoite antibodies in naturally exposed cats, and (d) evaluate associations between the serologic status of naturally exposed cats and clinical signs that could be caused by toxoplasmosis.
methodsTo generate positive control sera, three male cats were orally inoculated with approximately 100,000 sporulated oocysts of the ME49 strain of T. gondii. A human antisporozoite antibody ELISA was then adapted for use with cat sera. Detectable levels of antisporozoite IgG were found in two of the three experimentally inoculated cats. The sera of 100 healthy cats and 295 clinically ill cats were assessed in the prototype sporozoite ELISA and a commercially available tachyzoite ELISA.
resultsThe ELISA estimated that prevalence of antisporozoite IgG was 2% in healthy cats and 3.1% in clinically ill cats; in contrast, the overall estimated prevalence of antitachyzoite IgG was 15%. Only two of 395 cats (0.5%) had both antisporozoite and antitachyzoite IgG.
conclusionsWhile experimentally infected and naturally exposed cats developed antisporozoite antibodies, the low prevalence did not allow for the evaluation of associations among clinical signs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.